AEON Biopharma Q2 net loss narrows to $1.16 million; operating loss widens 36.44% to $5.92 million
AEON•Program update
- FDA reviewed the ABP-450 analytical similarity strategy in January; AEON targets completing most analytical comparability work in 2026.
Quarterly results and expense trends
- AEON Biopharma posted a GAAP net loss of $1.16 million for the quarter ended June 30, 2026, narrowing from a $6.64 million loss.
- Operating loss widened 36.44% to $5.92 million on higher R&D, while no revenue was reported.
- R&D expenses more than doubled to $2.94 million, driven by higher biosimilar R&D consulting costs.
- SG&A slipped 9% to $2.99 million, mainly on lower professional and legal fees.
Related News
Sabesp Q2 adjusted net income falls 38% to R$ 1.15 billion
SBS•
Lambda Prices $926 Million Senior Secured Term Loan B Facility, the First Investment-Grade-Rated Term Loan B Financing by a Private Neocloud
SMH•
